What is negative test result
8.—(1)  For the purposes of these Regulations, where an individual undergoes an approved test or tests consisting only of a polymerase chain reaction test or tests, the individual’s test result is treated as negative for SARS-CoV-2 only if —
(a)the test result from the sole polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual or the individual’s test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or
[S 590/2021 wef 10/08/2021]
(b)the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual’s last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2.
[S 590/2021 wef 10/08/2021]
(2)  For the purposes of these Regulations, where an individual undergoes an approved test or tests consisting only of an antigen rapid test or tests, the individual’s test result is treated as negative for SARS‑CoV‑2 only if —
(a)the antigen rapid test result from the sole antigen rapid test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual; or
(b)the test result from the last antigen rapid test the individual undergoes shows no presence of SARS‑CoV‑2 in that individual, after the individual undergoes further antigen rapid tests and the test results of those tests are uncertain or invalid except the last.
[S 768/2021 wef 11/10/2021]
(3)  For the purposes of these Regulations, where an individual undergoes a series of approved tests consisting of polymerase chain reaction tests and antigen rapid tests, the individual’s test result is treated as negative for SARS‑CoV-2 only if —
(a)the test results of the antigen rapid tests are uncertain or invalid, another respiratory specimen from the individual is then subjected to a polymerase chain reaction test, and —
(i)the test result from that polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV-2 in that individual or the individual’s test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or
[S 590/2021 wef 10/08/2021]
(ii)the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS-CoV-2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual’s last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or
[S 590/2021 wef 10/08/2021]
[S 768/2021 wef 11/10/2021]
(b)the test result of an antigen rapid test shows the presence of SARS‑CoV-2 in that individual, another respiratory specimen from the individual is then subjected to a polymerase chain reaction test, and —
(i)the test result from that polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV-2 in that individual or the individual’s test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2; or
[S 590/2021 wef 10/08/2021]
(ii)the test result from the last polymerase chain reaction test the individual undergoes shows no presence of SARS‑CoV-2 in that individual, after the individual undergoes further polymerase chain reaction tests and the test results of those tests are uncertain or invalid except the last, or the individual’s last test result shows the presence of SARS-CoV-2 in that individual but it is an atypical finding for SARS-CoV-2.
[S 590/2021 wef 10/08/2021]
(4)  Despite paragraphs (1), (2) and (3), a result of an antigen rapid test for the presence of SARS‑CoV-2 applied to an individual’s respiratory specimen must be disregarded for the purposes of these Regulations if —
(a)the relevant sampling activity taking the respiratory specimen from the individual was —
(i)not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant sampling activity is not self-administered; or
(ii)in the case of a self-administered relevant sampling activity performed by the individual on himself or herself, not supervised by an approved test provider; or
[S 768/2021 wef 11/10/2021]
(b)the relevant testing activity or the relevant assessment activity involving the respiratory specimen from the individual was —
(i)not performed in Singapore, or not performed by or under the direction of an approved test provider where the relevant testing activity or the relevant assessment activity is not self-administered; or
(ii)in the case of a self-administered relevant testing activity or a self-administered relevant assessment activity performed by the individual involving the respiratory specimen removed from himself or herself, not supervised by an approved test provider.
[S 768/2021 wef 11/10/2021]